MEI Pharma, Inc.
3611 Valley Centre Drive, Suite #500
About MEI Pharma, Inc.
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in Phase II clinical studies for advanced hematologic diseases. The Company is also developing ME-344, a novel mitochondrial inhibitor that has shown evidence of clinical activity in refractory solid tumors, and ME-401 (formerly PWT143), a highly selective, oral PI3K delta inhibitor. For more information, please visit www.meipharma.com.
CEO: Daniel Gold, PhD
Please click here for clinical trial information.
Please click here for Mei Pharma job opportunities.
237 articles with MEI Pharma, Inc.
MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
MEI Pharma, Inc. announced the publication of data abstracts related to two of MEI Pharma's clinical stage drug development programs to be presented at the 2019 ASCO Annual Meeting to be held May 31 to June 4, 2019 in Chicago.
MEI Pharma, Inc. reported results for its third quarter ended March 31, 2019.
MEI Remains in Strong Position as ME-401 Advances to Global Phase 2 Study to Support FDA Accelerated Approval
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
Helsinn Group and MEI Pharma, Inc. today announced interim data from a Phase 2 study evaluating pracinostat, a histone deacetylase inhibitor, in combination with azacitidine for the treatment of patients with IPSS-R high/very high-risk of Myelodysplastic Syndrome (MDS).
MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting
Data Support Complementary Potential of Intermittent and Continuous Dosing Schedules as Means to Optimize Clinical Risk-Benefit Ratio in Relapsed/Refractory Follicular Lymphoma Patients
MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data presented at the 2018 American Society of Hematology (ASH) annual meeting
MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End
MEI Pharma, Inc. today announced that Daniel P. Gold, Ph.D. will present a corporate update at the Stifel 2018 Healthcare Conference.
MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, "Kyowa Hakko Kirin"), today announced the execution of a license agreement granting Kyowa Hakko Kirin exclusive rights to develop and commercialize ME-401 in Japan
MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present data from three accepted abstracts related to MEI Pharma's clinical stage drug development programs at the 2018 ASH Annual Meeting to be held December 1-4, 2018 in San Diego.
MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies
MEI Pharma, Inc. and BeiGene, Ltd. today announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401
MEI Pharma to Release 2018 Fiscal Year End Financial Results and Provide Corporate Update on August 30, 2018
MEI Pharma, Inc. announced that the Company will release its 2018 fiscal year end financial results after the close of the U.S. financial markets on August 30, 2018.
MEI Pharma, Inc. announced that David M. Urso, J.D., the Company's senior vice president of corporate development and general counsel, was promoted to chief operating officer.
--Initiation of registration study for ME-401 in patients with relapsed or refractory follicular lymphoma expected before year-end--
MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
90% Objective Response Rate Observed in Patients with Indolent B-Cell Malignancies
MEI Pharma Presents Clinical Data for ME-344 in HER2 Negative Breast Cancer Patients at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
MEI Pharma, Inc. announced that data presented at ASCO 2018 from an investigator-initiated study of ME-344 in patients with HER2 negative breast cancer demonstrate evidence of inhibition of tumor proliferation as measured by Ki-67 reductions.
MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients
Predefined Patient Retention Threshold Met: 10% Early Discontinuation Rate Due to Adverse Events Supports Expansion of Patient Enrollment
AMRI's Michele Luche, vice president, Discovery Services, will be participating in a panel discussion on bridging the gap between early promise and clinic-ready compounds at the 2018 BIO International Convention.
MEI Pharma Grabs $75 Million Private Placement to Drive Registration Study for P13K Inhibitor Pro...
5/14/2018Shares of MEI Pharma, Inc. are up nearly 9 percent this morning after the company snagged $75 million in a private placement that was led by Vivo Capital and CAM Capital. The funds will be used to treat adults with relapsed or refractory follicular lymphoma with a P13K inhibitor.
MEI Pharma, Inc. today announced it entered into a definitive securities purchase agreement for the sale of its common stock and warrants to purchase common stock in a private placement led by Vivo Capital and CAM Capital.